MARKET

CDXS

CDXS

Codexis Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.49
+0.02
+0.19%
After Hours: 10.49 0 0.00% 16:34 05/20 EDT
OPEN
10.80
PREV CLOSE
10.47
HIGH
10.84
LOW
9.88
VOLUME
652.24K
TURNOVER
0
52 WEEK HIGH
42.01
52 WEEK LOW
9.47
MARKET CAP
685.04M
P/E (TTM)
-32.9460
1D
5D
1M
3M
1Y
5Y
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming investor conferences. The ...
GlobeNewswire · 4d ago
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its gene therapy programs are the subject of two poster prese...
GlobeNewswire · 6d ago
Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?
Codexis, Inc. ( NASDAQ:CDXS ), is not the largest company out there, but it received a lot of attention from a...
Simply Wall St. · 05/12 12:17
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:25
Codexis Q1 EPS $(0.13) Beats $(0.19) Estimate, Sales $35.30M Beat $28.58M Estimate; Reaffirms Guidance
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.19) by 31.58 percent. This is a 7.14 percent increase over losses of $(0.14) per share from the same
Benzinga · 05/05 21:31
Codexis GAAP EPS of -$0.13 beats by $0.06, revenue of $35.34M beats by $6.76M
Codexis press release (NASDAQ:CDXS): Q1 GAAP EPS of -$0.13 beats by $0.06. Revenue of $35.34M (+96.0% Y/Y) beats by $6.76M.
Seekingalpha · 05/05 20:14
-- Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $35.3M, vs. Street Est of $28.6M
MT Newswires · 05/05 16:53
Codexis Q1 2022 Earnings Preview
Codexis (NASDAQ:CDXS) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.15 (vs. -$0.14 last year) and the consensus Revenue Estimate is
Seekingalpha · 05/04 21:41
More
No Data
Learn about the latest financial forecast of CDXS. Analyze the recent business situations of Codexis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CDXS stock price target is 35.25 with a high estimate of 42.00 and a low estimate of 22.00.
High42.00
Average35.25
Low22.00
Current 10.49
EPS
Actual
Estimate
-0.17-0.12-0.07-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 211
Institutional Holdings: 63.77M
% Owned: 97.65%
Shares Outstanding: 65.30M
TypeInstitutionsShares
Increased
68
5.36M
New
16
264.60K
Decreased
47
9.12M
Sold Out
32
834.24K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
President/Chief Executive Officer/Director
John Nicols
Chief Financial Officer/Senior Vice President
Ross Taylor
Independent Director
Jennifer Aaker
Independent Director
Stephen Dilly
Independent Director
Byron Dorgan
Independent Director
Esther Martinborough
Independent Director
Alison Moore
Independent Director
David Smith
Independent Director
Dennis Wolf
Independent Director
Patrick Yang
No Data
No Data
About CDXS
Codexis, Inc. is a enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. The Company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. The Company’s products include Codex HiFi Hot Start DNA Polymerase and Codex HiCap RNA Polymerase. The Company serves various industries, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemical.

Webull offers kinds of Codexis, Inc. stock information, including NASDAQ:CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.